Search

Blood cancer is an extremely costly cancer to both patients and payers. According to The Leukemia and Lymphoma Society, the average annual spending for treating blood cancer is $156,000 in the first year after diagnosis1. Blood cancers include leukemia, lymphoma, myeloma, and bone marrow disorders. These cancers are also known to have higher out-of-pocket costs...

Black patients are more likely to present with advanced non-small cell lung cancer (NSCLC) and are less likely to receive surgery at higher residential segregation levels, according to a study presented at the annual meeting of the Society of Thoracic Surgeons, held virtually from Jan. 29 to 31. Chandler Annesi, from the Boston University School...

Every organ in the human body serves an important purpose in keeping it running and in prime condition. Most healthy people are not cognizant of their organs—like lungs—on a daily basis, because they are able to breathe without difficulty and perform their daily tasks without major effort. But damage to these vital organs can cause...

THURSDAY, Nov. 19, 2020 (HealthDay News) — Among patients with previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC), progression-free survival is significantly longer for those who receive first-line therapy with lorlatinib versus crizotinib, according to a study published in the Nov. 19 issue of the New England Journal of Medicine. Alice T. Shaw, M.D.,...

This study describes a deep learning algorithm model that facilitates accurate prediction of grading and staging of renal clear cell carcinoma and also promotes the optimization of individualized treatment plans. Deep learning algorithms were used to develop a model that allows the prediction of the grading and staging of renal clear cell carcinoma to facilitate...

Bimekizumab demonstrates overall greater efficacy than guselkumab in psoriatic arthritis patients at 52 weeks, according to an analysis of data from several trials. Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA). Recent Phase 3 trials have demonstrated the efficacy and safety of bimekizumab (an interleukin-17F and IL-17A inhibitor) and guselkumab (an interleukin-23 inhibitor) in...

The lack of minority representation in clinical trials is often explained as an unwillingness of minority patients to become involved. However, a study on barriers to recruiting underrepresented populations to cancer clinical trials demonstrates that the researcher may be responsible for this outcome. This study and others have found that providing additional information relevant to...

We are living longer, and our population is increasingly aging. Despite a growing need for clinical trials that benefit seniors, the median age of clinical trial participants is decreasing. A recent study examining clinical trial enrollment of over 262,000 patients with common cancer types between 1994 and 2015 found that the difference in the median...

When St. Jude opened in 1962, Danny Thomas vowed the hospital would treat patients regardless of race, religion or ability to pay. Dr. Rudolph Jackson was one of the first black doctors at St. Jude. While he was finishing his training in Philadelphia, Dr. Rudolph Jackson fielded an offer to move 1,000 miles and begin...

FRIDAY, Oct. 16, 2020 (HealthDay News) — For patients with diabetes mellitus and obesity, bariatric surgery (BS) is associated with a reduced prevalence of pancreatic cancer compared with no BS, according to a study presented at UEG Week Virtual 2020, held Oct. 11 to 13. Aslam Syed, M.D., from Allegheny Health Network in Pittsburgh and...